Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
8.57
-0.13 (-1.49%)
Mar 14, 2025, 10:55 AM EDT - Market open

Company Description

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.

The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage.

It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers.

Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals logo
Country United States
Founded 2018
IPO Date May 27, 2021
Industry Biotechnology
Sector Healthcare
Employees 181
CEO Jeremy Bender

Contact Details

Address:
1800 Sierra Point Parkway, Suite 200
Brisbane, California 94005
United States
Phone 650 484 0899
Website dayonebio.com

Stock Details

Ticker Symbol DAWN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001845337
CUSIP Number 23954D109
ISIN Number US23954D1090
Employer ID 83-2415215
SIC Code 2834

Key Executives

Name Position
Dr. Jeremy Bender M.B.A., Ph.D. Chief Executive Officer, President and Director
Charles N. York II, M.B.A. Chief Operating Officer, Chief Financial Officer and Secretary
Adam Dubow J.D. General Counsel and Chief Compliance Officer
John Stubenrauch Ph.D. Chief Technology Officer
Jaa Roberson Chief People Officer
Dr. Davy Chiodin Ph.D., Pharm.D. Chief Development Officer
Lauren Merendino M.B.A. Chief Commercial Officer
Dr. Elly Barry M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 6, 2025 10-K/A [Amend] Annual report
Feb 25, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 18, 2025 144 Filing
Feb 18, 2025 144 Filing
Feb 18, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Jan 10, 2025 S-8 Securities to be offered to employees in employee benefit plans